Contractile deficits in engineered cardiac microtissues as a result of MYBPC3 deficiency and mechanical overload

The integration of in vitro cardiac tissue models, human induced pluripotent stem cells (hiPSCs) and genome-editing tools allows for the enhanced interrogation of physiological phenotypes and recapitulation of disease pathologies. Here, using a cardiac tissue model consisting of filamentous three-dimensional matrices populated with cardiomyocytes derived from healthy wild-type (WT) hiPSCs (WT hiPSC-CMs) or isogenic hiPSCs deficient in the sarcomere protein cardiac myosin-binding protein C (MYBPC3–/– hiPSC-CMs), we show that the WT microtissues adapted to the mechanical environment with increased contraction force commensurate to matrix stiffness, whereas the MYBPC3–/– microtissues exhibited impaired force development kinetics regardless of matrix stiffness and deficient contraction force only when grown on matrices with high fibre stiffness. Under mechanical overload, the MYBPC3–/– microtissues had a higher degree of calcium transient abnormalities, and exhibited an accelerated decay of calcium dynamics as well as calcium desensitization, which accelerated when contracting against stiffer fibres. Our findings suggest that MYBPC3 deficiency and the presence of environmental stresses synergistically lead to contractile deficits in cardiac tissues.Cardiac tissue engineered to enable the modulation of mechanical resistance to tissue contraction facilitates the modelling of genetic pathologies associated with the absence of a thick-filament accessory protein found in striated heart muscle.

[1]  K. McDonald,et al.  Hypertrophic Cardiomyopathy in Cardiac Myosin Binding Protein-C Knockout Mice , 2002, Circulation research.

[2]  Thomas Eschenhagen,et al.  Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice. , 2013, Journal of molecular and cellular cardiology.

[3]  George Church,et al.  Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy , 2015, Science.

[4]  B. Cui,et al.  Chemically Defined and Small Molecule-Based Generation of Human Cardiomyocytes , 2014, Nature methods.

[5]  Deepak Srivastava,et al.  Contractility of single cardiomyocytes differentiated from pluripotent stem cells depends on physiological shape and substrate stiffness , 2015, Proceedings of the National Academy of Sciences.

[6]  F. Weinberger,et al.  Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice , 2012, Journal of molecular and cellular cardiology.

[7]  C. Grigoropoulos,et al.  Fabrication of arbitrary polymer patterns for cell study by two-photon polymerization process. , 2009, Journal of biomedical materials research. Part A.

[8]  Fu Siong Ng,et al.  Processing and analysis of cardiac optical mapping data obtained with potentiometric dyes. , 2012, American journal of physiology. Heart and circulatory physiology.

[9]  遠山 周吾 Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes , 2013 .

[10]  P. Powers,et al.  Dissociation of Structural and Functional Phenotypes in Cardiac Myosin-Binding Protein C Conditional Knockout Mice , 2012, Circulation.

[11]  Eduardo Kausel,et al.  Integrated Analysis of Contractile Kinetics, Force Generation, and Electrical Activity in Single Human Stem Cell-Derived Cardiomyocytes , 2015, Stem cell reports.

[12]  J. Bechhoefer,et al.  Calibration of atomic‐force microscope tips , 1993 .

[13]  K. McDonald,et al.  Loaded Shortening, Power Output, and Rate of Force Redevelopment Are Increased With Knockout of Cardiac Myosin Binding Protein-C , 2003, Circulation research.

[14]  Satoshi Kawata,et al.  Finer features for functional microdevices , 2001, Nature.

[15]  K. Webster,et al.  Quantitative Control of Adaptive Cardiac Hypertrophy by Acetyltransferase p300 , 2008, Circulation.

[16]  Nathaniel Huebsch,et al.  Automated Video-Based Analysis of Contractility and Calcium Flux in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Cultured over Different Spatial Scales. , 2015, Tissue engineering. Part C, Methods.

[17]  L. Carrier,et al.  Cardiac myosin-binding protein C (MYBPC3) in cardiac pathophysiology. , 2015, Gene.

[18]  R. Moss,et al.  Cardiac MyBP-C regulates the rate and force of contraction in mammalian myocardium. , 2015, Circulation research.

[19]  J. Strande Haploinsufficiency MYBPC3 mutations: another stress induced cardiomyopathy? Let's take a look! , 2015, Journal of molecular and cellular cardiology.

[20]  Nevan J Krogan,et al.  CRISPR Interference Efficiently Induces Specific and Reversible Gene Silencing in Human iPSCs. , 2016, Cell stem cell.

[21]  Thomas Rau,et al.  Human Engineered Heart Tissue as a Versatile Tool in Basic Research and Preclinical Toxicology , 2011, PloS one.

[22]  Sean P. Palecek,et al.  Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions , 2012, Nature Protocols.

[23]  J. Kelly,et al.  Pulmonary Hypertension Predicts Mortality and Morbidity in Patients with Dilated Cardiomyopathy , 1992, Annals of Internal Medicine.

[24]  Hirofumi Hidai,et al.  Self-standing aligned fiber scaffold fabrication by two photon photopolymerization , 2009, Biomedical microdevices.

[25]  David L Kaplan,et al.  Electrical and mechanical stimulation of cardiac cells and tissue constructs. , 2016, Advanced drug delivery reviews.

[26]  M. Gautel,et al.  The C-protein (myosin binding protein C) family: regulators of contraction and sarcomere formation? , 1999, Reviews of physiology, biochemistry and pharmacology.

[27]  J. Fischer,et al.  Elastic Fully Three‐dimensional Microstructure Scaffolds for Cell Force Measurements , 2010, Advanced materials.

[28]  K Ann McKibbon,et al.  Current status and future prospects. , 2008, Health information and libraries journal.

[29]  Christine L. Mummery,et al.  Contractile Defect Caused by Mutation in MYBPC3 Revealed under Conditions Optimized for Human PSC-Cardiomyocyte Function , 2015, Cell reports.

[30]  Eleonora Savio-Galimberti,et al.  Electrophysiologic Characterization of Calcium Handling in Human Induced Pluripotent Stem Cell-Derived Atrial Cardiomyocytes , 2018, Stem cell reports.

[31]  K. Musunuru Genome editing of human pluripotent stem cells to generate human cellular disease models , 2013, Disease Models & Mechanisms.

[32]  J. Molkentin,et al.  The Transcription Factors GATA4 and dHAND Physically Interact to Synergistically Activate Cardiac Gene Expression through a p300-dependent Mechanism* , 2002, The Journal of Biological Chemistry.

[33]  A. Hoeft,et al.  Myocardial injury modulates the innate immune system and changes myocardial sensitivity , 2006, Basic Research in Cardiology.

[34]  M. Suematsu,et al.  Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. , 2013, Cell stem cell.

[35]  Kam W Leong,et al.  Pluripotent stem cell-derived cardiac tissue patch with advanced structure and function. , 2011, Biomaterials.

[36]  M. Radisic,et al.  Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues. , 2016, Advanced drug delivery reviews.

[37]  Luke P. Lee,et al.  Human iPSC-based Cardiac Microphysiological System For Drug Screening Applications , 2015, Scientific Reports.

[38]  Tessa R Werner,et al.  Deciphering the microRNA signature of pathological cardiac hypertrophy by engineered heart tissue- and sequencing-technology. , 2015, Journal of molecular and cellular cardiology.

[39]  Kevin E Healy,et al.  In vitro cardiac tissue models: Current status and future prospects. , 2016, Advanced drug delivery reviews.

[40]  Raymond B. Runyan,et al.  Dynamic Myofibrillar Remodeling in Live Cardiomyocytes under Static Stretch , 2016, Scientific Reports.

[41]  R. Moss,et al.  Neonatal Mouse–Derived Engineered Cardiac Tissue: A Novel Model System for Studying Genetic Heart Disease , 2011, Circulation research.

[42]  Kevin E. Healy,et al.  Miniaturized iPS-Cell-Derived Cardiac Muscles for Physiologically Relevant Drug Response Analyses , 2016, Scientific Reports.

[43]  Gordana Vunjak-Novakovic,et al.  Autonomous beating rate adaptation in human stem cell-derived cardiomyocytes , 2016, Nature Communications.

[44]  Deepak Srivastava,et al.  Multi-Imaging Method to Assay the Contractile Mechanical Output of Micropatterned Human iPSC-Derived Cardiac Myocytes , 2017, Circulation research.

[45]  Praveen Shukla,et al.  Chemically defined generation of human cardiomyocytes , 2014, Nature Methods.

[46]  Kevin Kit Parker,et al.  Recapitulating maladaptive, multiscale remodeling of failing myocardium on a chip , 2013, Proceedings of the National Academy of Sciences.

[47]  Kumaraswamy Nanthakumar,et al.  Design and formulation of functional pluripotent stem cell-derived cardiac microtissues , 2013, Proceedings of the National Academy of Sciences.

[48]  Adam J Engler,et al.  Embryonic cardiomyocytes beat best on a matrix with heart-like elasticity: scar-like rigidity inhibits beating , 2008, Journal of Cell Science.

[49]  D. Warshaw,et al.  Molecular Mechanics of Cardiac Myosin-Binding Protein C in Native Thick Filaments , 2012, Science.

[50]  K. Node,et al.  Endothelin‐1 Induces Myofibrillar Disarray and Contractile Vector Variability in Hypertrophic Cardiomyopathy–Induced Pluripotent Stem Cell–Derived Cardiomyocytes , 2014, Journal of the American Heart Association.

[51]  Wesley R. Legant,et al.  Microfabricated tissue gauges to measure and manipulate forces from 3D microtissues , 2009, Proceedings of the National Academy of Sciences.

[52]  Teodor Gotszalk,et al.  Calibration of atomic force microscope , 2008 .

[53]  Aibin He,et al.  Co-occupancy by multiple cardiac transcription factors identifies transcriptional enhancers active in heart , 2011, Proceedings of the National Academy of Sciences.

[54]  M. Fujita,et al.  Cyclin-dependent Kinase-9 Is a Component of the p300/GATA4 Complex Required for Phenylephrine-induced Hypertrophy in Cardiomyocytes* , 2010, The Journal of Biological Chemistry.

[55]  M. Gautel,et al.  Isoform transitions of the myosin binding protein C family in developing human and mouse muscles: lack of isoform transcomplementation in cardiac muscle. , 1998, Circulation research.

[56]  Euan A Ashley,et al.  Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. , 2013, Cell stem cell.

[57]  B. Spiegelman,et al.  C/EBPβ Controls Exercise-Induced Cardiac Growth and Protects against Pathological Cardiac Remodeling , 2010, Cell.

[58]  Thomas Eschenhagen,et al.  Increased afterload induces pathological cardiac hypertrophy: a new in vitro model , 2012, Basic Research in Cardiology.

[59]  Kevin D. Costa,et al.  Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[60]  Axel Visel,et al.  Dynamic GATA4 enhancers shape the chromatin landscape central to heart development and disease , 2014, Nature Communications.

[61]  Nathaniel Huebsch,et al.  Three-dimensional filamentous human diseased cardiac tissue model. , 2014, Biomaterials.

[62]  R. Beygui,et al.  Immunobiology of Fibrin‐Based Engineered Heart Tissue , 2015, Stem cells translational medicine.

[63]  Kevin Kit Parker,et al.  Structural Phenotyping of Stem Cell-Derived Cardiomyocytes , 2015, Stem cell reports.